Galderma Ebit from 2010 to 2026
| GALD Stock | 145.90 0.20 0.14% |
EBIT | First Reported 2010-12-31 | Previous Quarter 765.9 M | Current Value 481.8 M | Quarterly Volatility 165.6 M |
Check Galderma Group financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Galderma Group's main balance sheet or income statement drivers, such as Depreciation And Amortization of 265.5 M, Interest Expense of 418 M or Selling General Administrative of 495.8 M, as well as many indicators such as Price To Sales Ratio of 3.27, Dividend Yield of 0.0 or PTB Ratio of 3.29. Galderma financial statements analysis is a perfect complement when working with Galderma Group Valuation or Volatility modules.
Galderma | Ebit |
The evolution of Ebit for Galderma Group N provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Galderma Group compares to historical norms and industry peers.
Latest Galderma Group's Ebit Growth Pattern
Below is the plot of the Ebit of Galderma Group N over the last few years. It is Galderma Group's EBIT historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Galderma Group's overall financial position and show how it may be relating to other accounts over time.
| Ebit | 10 Years Trend |
|
Ebit |
| Timeline |
Galderma Ebit Regression Statistics
| Arithmetic Mean | 336,903,447 | |
| Geometric Mean | 309,702,910 | |
| Coefficient Of Variation | 49.15 | |
| Mean Deviation | 126,746,103 | |
| Median | 247,949,053 | |
| Standard Deviation | 165,602,294 | |
| Sample Variance | 27424.1T | |
| Range | 518M | |
| R-Value | 0.72 | |
| Mean Square Error | 14075T | |
| R-Squared | 0.52 | |
| Significance | 0 | |
| Slope | 23,621,828 | |
| Total Sum of Squares | 438785.9T |
Galderma Ebit History
About Galderma Group Financial Statements
Galderma Group investors use historical fundamental indicators, such as Galderma Group's Ebit, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Galderma Group. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| EBIT | 765.9 M | 481.8 M | |
| EBITDA | 1.1 B | 747.4 M | |
| Ebt Per Ebit | 0.43 | 0.45 | |
| Ebit Per Revenue | 0.13 | 0.10 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Galderma Stock Analysis
When running Galderma Group's price analysis, check to measure Galderma Group's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Galderma Group is operating at the current time. Most of Galderma Group's value examination focuses on studying past and present price action to predict the probability of Galderma Group's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Galderma Group's price. Additionally, you may evaluate how the addition of Galderma Group to your portfolios can decrease your overall portfolio volatility.